Suraksha Diagnostic Ltd
Suraksha Diagnostic Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Top 10 Healthcare Services companies on management guidance
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
The company expects steady revenue growth, targeting around 15% annually, reflecting a conservative approach as they mature their operations. Revenue growth guidance is a conservative 15% in FY '27 but management aims for robust growth fueled by network expansion and new geographies. - EBITDA margins expected to increase; mature centers have achieved ~40.9% EBITDA margin, with overall target around 34% margin sustainable through FY '28 and beyond. - Genomic business, contributing margins around 15-20%, expected to witness strong continued growth and is a key growth pillar. - Test volume growth steady though moderate (~10-11% in Q1 FY '27), with potential to improve as genomic testing gains traction. - New centers currently breaking even within months, expected to improve overall profitability as they scale. - Company expanding aggressively toward 100 centers by FY '28, investing Rs.
From Suraksha Diagnostic Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- The company expects steady revenue growth, targeting around 15% annually, reflecting a conservative approach as they mature their operations.
- Test volume growth has been robust historically (~20% YoY), though recent quarters showed some moderation (~10-11%). Volume growth remains a key driver.
- Expansion plans include adding approximately 20 new labs in FY '27, with about 50% of new centers in newer geographies beyond core regions like Kolkata and West Bengal.
- Genomics business is seen as a significant growth pillar, with strong adoption and market education efforts underway; expected to contribute meaningfully over the next 3-4 years.
- Mature centers showed ~12.5% revenue growth quarter-on-quarter, expected to sustain this momentum.
2 more points from Suraksha Diagnostic Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Suraksha Diagnostic Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Genomic Capacity Investment: Rs. 22 crores invested over 3 years in genomic labs (Page 15).
- Future Genomics Capex: No substantial incremental CapEx expected in genomics for the next 2-3 years; existing CapEx is sufficient to leverage growth (Page 10).
- FY '27 Capex Outlook: Rs. 70-80 crores planned for the financial year for network expansion (Page 6).
- Center Expansion: Plan to open 6 spokes and 3 hubs in the current year, beyond centers already opened (Page 10).
2 more points from Suraksha Diagnostic Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Suraksha Diagnostic Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Suraksha Diagnostic Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹81 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Suraksha Diagno.'s management said in earlier quarters
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Suraksha Diagnostic Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Suraksha Diagnostic Ltd Q1 FY27 results?
The company expects steady revenue growth, targeting around 15% annually, reflecting a conservative approach as they mature their operations. Revenue growth guidance is a conservative 15% in FY '27 but management aims for robust growth fueled by network expansion and new geographies. - EBITDA margins expected to increase; mature centers have achieved ~40.9% EBITDA margin, with overall target around 34% margin sustainable through FY '28 and beyond. - Genomic business, contributing margins around 15-20%, expected to witness strong continued growth and is a key growth pillar. - Test volume growth steady though moderate (~10-11% in Q1 FY '27), with potential to improve as genomic testing gains traction. - New centers currently breaking even within months, expected to improve overall profitability as they scale. - Company expanding aggressively toward 100 centers by FY '28, investing Rs.
What is Suraksha Diagnostic Ltd share price analysis?
Suraksha Diagnostic Ltd currently shows a below-average growth signal. The stock trades at a P/E of 44.4 with a market cap of ₹1,588 Cr. Investors should review the full earnings analysis for detailed insights.
Is Suraksha Diagnostic Ltd planning capital expenditure?
Genomic Capacity Investment: Rs.
Keep Suraksha Diagnostic Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.